Get Level 2
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Immupharma Share Price
  4. Immupharma Share Regulatory News
  5. Euronext Delisting

Pin to quick picksImmupharma Regulatory News (IMM)

Immupharma Information

Share Price Information for Immupharma (IMM)

Share Price is delayed by 15 minutes
Get Live Data
4.045    0.045 (1.13%)
Bid:
3.80
Ask:
4.295
Spread: 0.495 (13.026%)
Market Cap: £25.24m
IMM Live PriceLast checked at - London Stock Exchange

Intraday Immupharma Share Chart

Euronext Delisting

1 Oct 2021 07:00

RNS Number : 6313N
Immupharma PLC
01 October 2021
 

 

RNS | 1 OCTOBER 2021

ImmuPharma PLC

("ImmuPharma", the "Company" or the "Group")

EURONEXT DELISTING

Date: 18 October 2021

ImmuPharma PLC (LSE:IMM; Euronext Growth Brussels: ALIMM),  the specialist drug discovery and development company, provides an update on its delisting from the Euronext Growth Brussels market, where it has a dual listing with AIM. This proposed de-listing from Euronext Growth Brussels was recently confirmed in the Company's 'Corporate Update' announcement on 29 September 2021.

The Company has received confirmation that the Euronext Listing Board has approved its voluntary delisting request from Euronext Growth Brussels.

The timeframe of the de-listing has been agreed with Euronext. It is envisaged that the shares of ImmuPharma (ISIN: GB0033711010) will be removed from trading on Euronext Growth Brussels, as from the 18 October 2021.

Below is a summary of the delisting schedule as disclosed:

DATE

EVENT

15 October 2021

Last day of trading of ImmuPharma's shares on Euronext Growth Brussels

18 October 2021

ImmuPharma's shares de-listed from Euronext Growth Brussels

 

End

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

For further information please contact:

 

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chief Executive Officer & Chairman

+ 44 (0) 207 152 4080

Lisa Baderoon, Head of Investor Relations & Non-Executive Director

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge

John Howes

Bob Pountney

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 368 3550

 

 

+44 20 3650 3650

 

 

 

 

+44 (0) 1483 413500

 

 

4Reliance (Euronext Growth Listing Sponsor)

Jean-Charles Snoy

 

Degroof Petercam (Liquidity Provider)

Erik De Clippel

 

Backstage Communication

Olivier Duquaine

Gunther De Backer

+32 (0) 2 747 02 60

 

 

+32 (0) 2 287 95 34

 

 

 

+32 (0) 477 504 784

+32 (0) 475 903 909

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 trial for Lupuzor™ and commercialise in the US.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk 

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDKKBBABKDDCN
234567891011
Date   Source Headline
2nd Jun 20165:26 pmRNSDirector/PDMR Shareholding
31st May 201610:38 amRNSHolding(s) in Company
26th May 20162:00 pmRNSResult of AGM
25th May 20167:00 amRNSHolding(s) in Company
4th May 20167:01 amRNSAnnual Financial Report & Notice of AGM
4th May 20167:00 amRNSFinal Results
26th Apr 20167:00 amRNSNotice of Results
22nd Apr 20169:50 amRNSHolding(s) in Company
9th Mar 20167:00 amRNSFirst European Site Opens - Patient Recruitment
8th Mar 201611:10 amRNSHolding(s) in Company
7th Mar 20163:31 pmRNSHolding(s) in Company
1st Mar 20167:00 amRNSEIS and VCT Qualifying Status and Issue of Equity
29th Feb 20168:02 amRNSHolding(s) in Company
24th Feb 201612:35 pmRNSIssue of Equity
22nd Feb 20161:39 pmRNSResult of GM
15th Feb 20167:00 amRNSUS PATIENTS COMMENCE DOSING IN PHASE III STUDY
5th Feb 201612:22 pmRNSPlacing and Subscription Raises £8.3 million
5th Feb 20167:00 amRNSProposed Placing and Subscription
21st Jan 20165:33 pmRNSHolding(s) in Company
15th Dec 20157:00 amRNSImmuPharma & Simbec-Orion - Investigators Meeting
7th Dec 20157:00 amRNSUpdate on the progress of Lupuzor
30th Nov 201511:55 amRNSHolding(s) in Company
4th Nov 20158:26 amRNSLupuzor Phase III Pivotal Trial Update
4th Nov 20157:00 amRNSLupuzor Phase III Pivotal Trial Update
23rd Oct 20157:00 amRNSDirectorate Change
30th Sep 20157:05 amRNSDirectorate Change
30th Sep 20157:00 amRNSInterim Results
29th Jul 20157:00 amRNSRichard Warr
27th Jul 20157:00 amRNSTERM SHEET SIGNED $14 MILLION FUNDING FOR LUPUZOR
25th Jun 20157:00 amRNSLupuzor's Founder Dr Slyviane Muller Awarded Medal
29th May 201512:50 pmRNSResult of AGM
6th May 20153:44 pmRNSAnnual Report & Accounts
6th May 20157:02 amRNSInterim Board Change
30th Apr 20157:05 amRNSDirectorate Change
30th Apr 20157:00 amRNSPreliminary Results
11th Feb 201512:02 pmRNSCANCER UPDATE: IPP-204106
27th Jan 20157:00 amRNSEnterprise Investment Scheme Status
22nd Jan 20157:00 amRNSCollaboration Agreement with Simbec-Orion
30th Oct 201411:10 amRNSHolding(s) in Company
28th Oct 20147:00 amRNSHolding(s) in Company
21st Oct 20147:00 amRNSAdditional Listing - Conditional Placing
20th Oct 20147:00 amRNSImmuPharma awarded EUR400,000 Grant
30th Sep 20147:05 amRNSHalf Yearly Report
30th Sep 20147:00 amRNSLupuzorT Gears Up To Start Pivotal Phase III trial
27th Jun 20141:11 pmRNSResult of AGM
27th Jun 20147:00 amRNSAccess to pioneering research in Bordeaux France
16th Jun 20147:00 amRNSNEW NUCANT PATENTS
23rd May 20147:00 amRNSAnnual Financial Report
21st May 20147:00 amRNSPreliminary Results
6th May 201412:47 pmRNSDr. Sylviane Muller - Presentation Abstract
234567891011

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
KYGA
Kerry
LSE
1.21%
CHLL
Chill Brands
LSE
0.00%
JUSC
Jpmorg.us
LSE
-0.77%
BRWM
BlackRock World Mining Trust plc
LSE
0.91%
RKH
Rockhopper
LSE
-3.16%
Trending
CPI
Capita
LSE
3.62%
EZJ
easyJet
LSE
14.28%
QED
Quadrise
LSE
1.01%
GST
GSTechnologies
LSE
4.04%
GGP
Greatland Resources
LSE
-0.61%